This study provides the first mechanistic evidence linking sitagliptin exposure to BP via IL-6-mediated immune dysregulation. Our findings highlight the potential dermatotoxic and immunotoxic risks of pharmaceutical contaminants in the environment and underscore the importance of integrating network toxicology with experimental approaches for environmental health risk assessment.
Feng et al. (Thu,) studied this question.